Technical CommentsCancer

Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

+ See all authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaam6298
DOI: 10.1126/scitranslmed.aam6298

You are currently viewing the abstract.

View Full Text

Abstract

OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines.

View Full Text